Background Peritoneal carcinomatosis is a common evolution in ovarian cancers. Although majority of patients have option of cytoreductive surgery and HIPEC, a few with recurrent cancers who are not eligible for curative approach can undergo pressurized intraperitoneal aerosol chemotherapy (PIPAC) which is an emerging ﬁeld of research with major therapeutic potential. It is a safe and innovative approach, which enhances the effect of chemotherapy without major toxicity. Methods Between June 2017 and December 2017, 9 PIPAC applications in 3 patients with pressurized aerosol solution of cisplatin and doxorubicin every 6 weeks at 37 C and 12 mmHg for 30 min were performed. The patient demographics, perioperative ﬁndings, adverse events, and outcomes were prospectively recorded. Results Nine PIPAC administrations were performed in 3 patients with peritoneal carcinomatosis secondary to ovarian cancer. The median hospital stay was 1 day. There were no major perioperative complications. CTCAE grade 2 was observed in 1 patient, for abdominal pain and nausea. Renal and hepatic functions were not impaired. Of the 3 patients, two patients had partial response, and one had stable disease. Conclusion Our results show the feasibility and safety of PIPAC in Indian patients with advanced ovarian cancer. The procedure has low morbidity
Indian Journal of Gynecologic Oncology – Springer Journals
Published: Apr 16, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera